

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity ZELIRA THERAPEUTICS LIMITED	
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Osagie Imasogie
Date of last notice	19 December 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	17 January 2025
No. of securities held prior to change	A. 428,883 ordinary shares B. 335,094 Class B performance rights C. 30,000 - unlisted options expiring 24/11/2027 @ \$2.00 D. 30,000 - unlisted options expiring 24/11/2027 @ \$4.00 E. 30,000 - unlisted options expiring 24/11/2027 @ \$6.00 F. 30,000 - unlisted options expiring 24/11/2027 @ \$8.00 G. 30,000 - unlisted options expiring 24/11/2027 @ \$10.00 H. 3,500,000 Convertible Notes
Class	B. Class B performance rights
Number acquired	
Number disposed	335,094

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A
No. of securities held after change	A. 428,883 ordinary shares B. C. 30,000 - unlisted options expiring 24/11/2027 @ \$2.00 D. 30,000 - unlisted options expiring 24/11/2027 @ \$4.00 E. 30,000 - unlisted options expiring 24/11/2027 @ \$6.00 F. 30,000 - unlisted options expiring 24/11/2027 @ \$8.00 G. 30,000 - unlisted options expiring 24/11/2027 @ \$10.00 H. 3,500,000 Convertible Notes
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Lapsed because conditions have not been met.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
--	-----

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity ZELIRA THERAPEUTICS LIMITED	
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Oludare Odumosu
Date of last notice	24 November 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	17 January 2025
No. of securities held prior to change (post 175:1 consolidation)	A. 131,766 ordinary shares B. 100,334 Class B performance rights C. 40,000 - unlisted options expiring 24/11/2027 @ \$2.00 D. 40,000 - unlisted options expiring 24/11/2027 @ \$4.00 E. 40,000 - unlisted options expiring 24/11/2027 @ \$6.00 F. 40,000 - unlisted options expiring 24/11/2027 @ \$8.00 40,000 - unlisted options expiring 24/11/2027 @ \$10.00
Class	B. Class B performance rights
Number acquired	
Number disposed	110,334
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	A. 131,766 ordinary shares B. C. 40,000 - unlisted options expiring 24/11/2027 @ \$2.00 D. 40,000 - unlisted options expiring 24/11/2027 @ \$4.00 E. 40,000 - unlisted options expiring 24/11/2027 @ \$6.00 F. 40,000 - unlisted options expiring 24/11/2027 @ \$8.00 G. 40,000 - unlisted options expiring 24/11/2027 @ \$10.00
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Lapsed because conditions have not been met.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.